GLP-1s Target Addiction: The Next Frontier for Incretin Therapies

GLP-1 receptor agonists, the class of drugs including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), have already revolutionized the treatment of type 2 diabetes and obesity. Now, a growing body of evidence suggests these therapies could be the next breakthrough in treating addiction, particularly for alcohol and opioid use disorders. This shift from metabolic health to behavioral health represents a significant pivot for the pharmaceutical industry and could dramatically expand the total addressable market for these therapies, which is currently underserved by existing pharmacological interventions.

The biological basis for this potential lies in the brain's complex reward circuitry. GLP-1 receptors are not just found in the gut and pancreas; they are also present in the ventral tegmental area (VTA) and the nucleus accumbens—regions of the brain central to the dopamine-driven reward system. By activating these receptors, GLP-1 drugs appear to modulate the release of dopamine in response to addictive substances. This essentially mutes the reward signal, making the substance less pleasurable and reducing the intense cravings that drive relapse. Unlike traditional addiction medications that often block receptors entirely, GLP-1s seem to recalibrate the reward threshold, providing a more nuanced approach to behavioral modification.

“

The University of North Carolina's pilot work has specifically highlighted semaglutide's ability to reduce binge-like drinking behaviors, a key metric for clinical success in alcohol use disorder (AUD) treatments.

While large-scale, Phase 3 clinical trials specifically for addiction are still in early stages, anecdotal evidence from patients treated for obesity has been overwhelming. Many report a sudden and profound loss of interest in alcohol, nicotine, and even compulsive behaviors like gambling or shopping. Early-stage trials, such as those conducted at the University of North Carolina and the University of Copenhagen, have shown promising results in reducing alcohol consumption in animal models and small human cohorts. Researchers are now moving toward more rigorous testing to determine if these effects are robust enough for FDA approval in addiction medicine. The University of North Carolina's pilot work has specifically highlighted semaglutide's ability to reduce binge-like drinking behaviors, a key metric for clinical success in alcohol use disorder (AUD) treatments.

For companies like Novo Nordisk and Eli Lilly, the addiction market represents a multi-billion dollar opportunity that could rival the obesity market in terms of social impact. Current treatments for AUD and opioid use disorder (OUD) have limited efficacy or low patient adherence due to side effects or the burden of daily dosing. If GLP-1s can provide a once-weekly injection that effectively curbs cravings, they could become the gold standard in a field that has seen little innovation in decades. However, this expansion also brings challenges, including the need for specialized clinical trial designs that account for the high placebo effect common in addiction studies and the ethical considerations of treating vulnerable populations with high-cost biologics.